Clinical trials: Polycythemia, open to volunteers
Polycythemia Vera (PV)
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
- Trial name
- NCT04655092
- Testing
- P1101 (Ropeginterferon alfa-2b)
- Where
- 6 sites in Japan
- Volunteers
- 67 people
- Sponsor
- PharmaEssentia Japan K.K.
Polycythemia Vera
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone.
- Trial name
- NCT07722611
- Testing
- Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Erythrocytosis, Polycythemia
EVAluation of Erythrocytosis PRospEctive Cohort STudy
The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin…
- Conditions
- Erythrocytosis, Polycythemia, Polycythemia Secondary, Polycythemia Vera
- Trial name
- EVEREST (NCT06785870)
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- Cyrus Hsia
Myeloid Malignancy
Therapeutic RSK1 Targeting in Myeloid Malignancies
This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms…
- Trial name
- NCT07379125
- Testing
- PMD-026
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Polycytemia Vera
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
This retrospective study aims to evaluate the effectiveness and safety of Ropeginterferon Alfa-2b (BESREMI) in patients with Polycythemia Vera (PV).
- Trial name
- MIRROR (NCT07282132)
- Testing
- Ropeginterferon alfa-2b (BESREMi®)
- Volunteers
- 150 people
- Sponsor
- Federico II University
Polycythemia Vera
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
- Trial name
- NCT06752746
- Testing
- 9MW3011
- Where
- 6 sites in China
- Volunteers
- 108 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or…
- Trial name
- ODYSSEY (NCT06517875)
- Testing
- Momelotinib, Luspatercept
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Myeloproliferative Neoplasms
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in…
- Trial name
- NCT07441694
- Testing
- INCA036978, Standard disease-directed therapy
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 218 people
- Sponsor
- Incyte Corporation
Polycythemia Secondary, Polycythemia, Primary
Blood Viscosity in Polycythemia Patients
Polycythemia (PG) corresponds to an increase in erythrocyte parameters on a blood test. A distinction is usually made between primary and secondary PG. The most common primary PG is Vaquez's disease, a hematological cancer.
- Trial name
- POLYVISCO (NCT06421025)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Hospices Civils de Lyon
Polycythemia Vera, Essential Thrombocythemia
A Study of GLB-001 in Patients With Myeloid Malignancies
Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
- Trial name
- NCT06378437
- Testing
- GLB-001
- Where
- 14 sites in China
- Volunteers
- 108 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Essential Thrombocythemia, Polycythemia Vera
Efficacy and Safety of Peginterferon in ET and PV.
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).
- Trial name
- NCT06734637
- Testing
- Peginterferon α-2b injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhenya Hong
Twin to Twin Transfusion Syndrome, Twin Anemia-Polycythemia Sequence
Evaluation of Laparotomy With Trans-Amniotic Suture Placement in TTTS Surgery
This is a randomized trial for patients that are diagnosed with Twin-Twin Transfusion Syndrome (TTTS) who are receiving a fetoscopic laser surgery to evaluate the effectiveness and safety of a laparotomy closure.
- Trial name
- TTTS TAPS (NCT06991400)
- Testing
- Trans-Amniotic Suture Placement
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Polycythemia Vera
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Polycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution.
- Trial name
- NCT06506084
- Testing
- Ropeginterferon alfa-2b
- Where
- 37 sites in Italy, Poland
- Volunteers
- 429 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia
- Trial name
- NCT06218628
- Testing
- Talazoparib, pacritinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Myeloproliferative Disease, Polycythemia Vera
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML).
- Conditions
- Myeloproliferative Disease, Polycythemia Vera, Thrombocythemia Essential, Myelofibrosis, Primary
- Trial name
- ENERGIA (NCT07518940)
- Testing
- Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Carmen Fava
Myeloproliferative Neoplasm, MPN
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
- Conditions
- Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT05123365
- Testing
- N-Acetylcysteine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Essential Thrombocythemia, Polycythemia Vera
Ruxolitinib in Thrombocythemia and Polycythemia Vera
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- Trial name
- NCT04644211
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital